指南与共识脊柱关节炎

银屑病关节炎药物治疗的疗效与安全性:为2023年欧洲抗风湿病联盟银屑病关节炎管理建议更新提供的系统文献研究

Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
指南 / 共识 · Ann Rheum Dis · 2024-05-15

该系统文献研究检索2019年更新至2022年12月28日的文献,评估传统合成、生物及靶向合成改善病情抗风湿药治疗银屑病关节炎的疗效与安全性。疗效分析纳入38篇文章(30项试验),安全性分析纳入24篇文章(15项观察性研究、9项试验长期随访),安全性指标与2019年系统文献研究基本一致。

要点

  • 所研究的传统合成、生物及靶向合成改善病情抗风湿药在改善银屑病关节炎体征症状、身体功能和生活质量方面均有效。
  • 安全性分析纳入15项观察性研究和9项试验长期随访,评估糖皮质激素、TNF抑制剂、IL-17抑制剂、JAK抑制剂、IL-12/23抑制剂和PDE4抑制剂。
  • 安全性指标与2019年系统文献研究结果基本一致。

核心结论

  • 所研究的药物在改善银屑病关节炎体征和症状、身体功能及生活质量方面均有效。
  • 安全性指标与2019年系统文献研究结果基本一致。

研究设计与样本

  • 系统文献研究,检索Medline、EMBASE和Cochrane CENTRAL数据库,纳入2019年上次更新至2022年12月28日发表的文献。
  • 疗效分析筛选3946篇文章,最终分析38篇文章(30项试验);安全性分析筛选2055篇摘要,最终分析24篇文章(15项观察性研究、9项试验长期随访)。
  • 未进行荟萃分析。

主要发现

  • 疗效分析的化合物包括传统合成改善病情抗风湿药(来氟米特、甲氨蝶呤)、抑制IL-17的生物改善病情抗风湿药(比美吉珠单抗、布罗达鲁单抗、依奇珠单抗、izokibep、司库奇尤单抗)、抑制IL-23的生物改善病情抗风湿药(古塞奇尤单抗、瑞莎珠单抗、替拉珠单抗)、抑制IL-12/23的生物改善病情抗风湿药(乌司奴单抗)、抑制TNF的生物改善病情抗风湿药(阿达木单抗、培塞利珠单抗、依那西普、英夫利西单抗、戈利木单抗)以及Janus激酶抑制剂(brepocitinib、deucravacitinib、托法替布、乌帕替尼)。
  • 安全性分析评估了糖皮质激素、TNF抑制剂、IL-17抑制剂、JAK抑制剂、IL-12/23抑制剂和PDE4抑制剂(阿普米司特)。
  • 特别关注的不良事件包括感染(包括带状疱疹、流感和结核病)、恶性肿瘤、主要不良心血管事件、静脉血栓栓塞、肝脏疾病、实验室检查变化和精神不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To obtain an overview of recent evidence on efficacy and safety of pharmacological treatments in psoriatic arthritis (PsA). METHODS: This systematic literature research (SLR) investigated the efficacy and safety of conventional synthetic (cs), biological (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs) in patients with PsA. A systematic database search using Medline, EMBASE, Cochrane CENTRAL was conducted to identify relevant articles published since the previous update in 2019 until 28 December 2022. Efficacy was assessed in trials while for safety observational data were also considered. Adverse events of special interest were infections (including herpes zoster, influenza and tuberculosis), malignancies, major adverse cardiovascular events, venous thromboembolisms, liver disease, laboratory changes and psychiatric adverse events. No meta-analyses were performed. RESULTS: For efficacy, of 3946 articles screened, 38 articles (30 trials) were analysed. The compounds investigated included csDMARDs (leflunomide, methotrexate), bDMARDs inhibiting IL17 (bimekizumab, brodalumab, ixekizumab, izokibep, secukinumab,), IL-23 (guselkumab, risankizumab, tildrakizumab), IL-12/23 (ustekinumab) as well as TNF (adalimumab, certolizumab-pegol, etanercept, infliximab, golimumab) and Janus Kinase inhibitors (JAKi) (brepocitinib, deucravacitinib, tofacitinib, upadacitinib). The compounds investigated were efficacious in improving signs and symptoms of PsA, improving physical functioning and quality of life. For safety, 2055 abstracts were screened, and 24 articles analysed: 15 observational studies and 9 long-term follow-ups of trials, assessing glucocorticoids, TNFi, IL-17i, JAKi, IL-12/23i and PDE4i (apremilast). Safety indicators were generally coherent with the previous SLR in 2019. CONCLUSION: The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kerschbaumer A, Smolen JS, Ferreira RJO, et al. Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2024. PMID: 38503473. doi:10.1136/ard-2024-225534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。